Latest News | Zydus Gets USFDA Nod for Generic Drug to Treat Multiple Sclerosis

New Delhi, May 9 (PTI) Zydus Lifesciences on Friday said it has received approval from the US health regulator to market a generic medication to treat multiple sclerosis.

The company has received approval from the US Food and Drug Administration (USFDA) for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose prefilled syringes.

Also Read | Kolkata Fatafat Result Today: Kolkata FF Result for May 09, 2025 Declared, Check Winning Numbers and Result Chart of Satta Matka-Type Lottery Game.

The company's product is the generic version of Copaxone which is indicated for the treatment of relapsing forms of Multiple Sclerosis (MS).

Zydus said the product, developed in collaboration with Chemi S.p.A., will be manufactured entirely in Europe.

Also Read | Shillong Teer Results Today, May 09 2025: Winning Numbers, Result Chart for Shillong Morning Teer, Shillong Night Teer, Khanapara Teer, Juwai Teer and Jowai Ladrymbai.

"This approval underscores Zydus' leadership in bringing complex, differentiated generics to market, reinforcing our commitment to providing a comprehensive range of therapeutic choices for patients," Zydus Lifesciences MD Sharvil Patel said.

As per IQVIA MAT data, Glatiramer Acetate Injection had annual sales of USD 719 million in the US market.

Shares of Zydus Lifesciences were trading 0.48 per cent up at Rs 876 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)